Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival

Maybury, Bernard D; James, Lisa J; Phillips, Neil; Venkatadasari, Indrani; Qureshi, Iman; Riley, James; Talbot, Georgina; Moosai, Shivir; Giles, Hannah; Chadderton, Nicola; Dowds, James; Rakesh, Pallav; Crosland, Henry; Haslam, Aidan; Lane, Sarah; Vega Gonzalez, Monica; Davies, David; Cherian, George; Shenouda, Amir; Kaudlay, Praveen; Starczynski, Jane; Rudzki, Zbigniew; Chaganti, Sridhar

Affiliation

University Hospitals Birmingham NHS Foundation Trust; University Hospitals of the North Midlands NHS Trust; The Royal Wolverhampton NHS Trust; University Hospitals Coventry and Warwickshire NHS Foundation Trust; The Dudley Group NHS Foundation Trust; Shrewsbury and Telford Hospital NHS Trust; Walsall Healthcare NHS Trust; Sandwell and West Birmingham Hospitals NHS Trust

Publication date

2024-07-04

Subject

Oncology. Pathology.

Metadata

Show full item record

Abstract

A reciprocal t(3;8) BCL6::MYC fusion is common in large B cell lymphoma (LBCL) with MYC and BCL6 disruption. These pseudo-double hit cases are not adverse, whereas t(3;8) negative MYC/BCL6 lymphoma has an inferior prognosis relative to other MYC-rearranged LBCL.

Citation

Maybury BD, James LJ BSc (Hons), Phillips N, Venkatadasari I, Qureshi I, Riley JWE, Talbot G, Moosai S, Giles HV Dr, Chadderton N Mrs, Dowds J, Rakesh P, Crosland H, Haslam A, Lane S, Vega Gonzalez M, Davies D, Cherian G, Shenouda A, Kaudlay Sathyanarayana PK, Starczynski J, Rudzki Z, Chaganti S. Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival. Blood. 2024 Apr 22:blood.2024024048.

Type

Article